LAG-3 blockade reactivates the CD8 T cell expansion program to re-expand contracted clones in the tumor

Munetomo Takahashi,Mikiya Tsunoda,Hiroyasu Aoki,Masaki Kurosu,Haru Ogiwara,Shigeyuki Shichino,David Bending,Shumpei Ishikawa,James Thaventhiran,Kouji Matsushima,Satoshi Ueha

DOI: https://doi.org/10.1101/2024.07.05.601623

2024-07-09

Abstract:Effective cancer immunotherapy relies on the clonal proliferation and expansion of CD8 T cells in the tumor. However, our insights into clonal expansions are limited, owing to an inability to track the same clones in tumors over time. Here, we developed a multi-tumor mouse model system to track hundreds of expanding and contracting CD8 T cell clones over multiple timepoints in tumors of the same individual. Through coupling of clonal expansion dynamics and single-cell RNA/TCR-seq data, we identified a transcriptomic signature in PD-1 Ly108 precursor exhausted cells that strongly predicts rates of intratumoral clone expansion in mice and humans. We found that expression of the signature successfully stratifies melanoma patient outcomes to PD-1/PD-L1 blockade. Downregulation of the signature precedes clone contraction - a phase in which clones contract but maintain revivable precursor exhausted cells in the tumor. LAG-3 blockade - an FDA-approved therapy whose effects on CD8 T cell responses are currently unclear, re-activates the expansion signature, re-expanding pre-existing clones, including previously contracted clones. These findings reveal how the study of clonal expansion dynamics provide a powerful pan-immunotherapy signature for monitoring immunotherapies, including PD-1/PD-L1 and LAG-3 blockade, with implications for their future development.

Immunology